Stiripentol (DIACOMIT)
Antiepileptic (GABA-A positive allosteric modulator / CYP450 inhibitor)
Stiripentol (DIACOMIT)
Forms and strengths
Form: TabletStrength: 250 mg, 500 mg
References
Indication
- Stiripentol is used together with clobazam and valproate as add-on therapy for tonic-clonic seizures in Dravet syndrome (severe myoclonic epilepsy in infancy) that are not adequately controlled by clobazam and valproate alone.
- Stiripentol has not been shown to be effective for other types of epilepsy or epileptic syndromes.
- Stiripentol is not established as safe or effective when used alone (monotherapy) for Dravet syndrome.
Pregnancy
- Stiripentol should not be used during pregnancy unless the expected benefit clearly outweighs the potential risk to the fetus.
- No controlled studies of stiripentol have been conducted in pregnant women, and there is no human pregnancy exposure data.
- Unlike many other antiepileptic drugs, stiripentol was not teratogenic in animal reproduction studies in rats and rabbits.
- Antiepileptic drugs as a class can cause fetal harm, and pregnancy registries show a two- to three-fold higher rate of malformations in infants exposed to antiepileptic drugs compared with the general population.
Breastfeeding
- Breastfeeding is not recommended during stiripentol treatment.
- Stiripentol passes freely from plasma into milk in animal studies (goats), and there is no human data on its excretion into breast milk.
Geriatrics
- There is no clinical experience with stiripentol in Dravet syndrome patients over 65 years of age.
- Age-related declines in liver and kidney function should be considered, since stiripentol is metabolized by the liver and its metabolites are cleared by the kidney.
Pediatrics
- Stiripentol is approved for use in children 3 years of age and older with confirmed Dravet syndrome.
- Use in children younger than 3 years must be individualized, weighing potential benefits and risks, and should only start once the Dravet syndrome diagnosis is clinically confirmed.
- Data on stiripentol use under 12 months of age are limited, and treatment in this age group should be closely supervised by a physician.
Dosage & Administration
- Stiripentol is started using an upward dose escalation over 3 days to reach the recommended maintenance dose, given together with clobazam and valproate, in 2 or 3 divided doses.
- There is no clinical evidence to support doses above the recommended maximum, or use of stiripentol as monotherapy.
- Starting stiripentol usually requires the clobazam dose to be reduced, since stiripentol markedly raises clobazam and norclobazam blood levels; the valproate dose may also need to be lowered if gastrointestinal side effects such as appetite or weight loss occur.
- In patients with liver or kidney impairment, treatment is started at the standard dose, with further titration guided by seizure control and tolerability rather than by a fixed adjustment, since formal studies of stiripentol pharmacokinetics have not been done in these populations.
- Switching between the capsule and powder for suspension formulations should be done under clinical supervision, since the powder produces a slightly higher peak blood level.
- If DIACOMIT is stopped, the dose should be tapered gradually over at least a month to reduce the risk of rebound or worsening seizures; more rapid withdrawal requires closer monitoring.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no human data on stiripentol overdose.
- In animal studies, high doses caused decreased motor activity and reduced respiration.
- Management should be supportive, with symptomatic care in an intensive care setting.
Common side effects
- Drowsiness or sleepiness may occur, and was the most frequently reported effect in clinical trials.
- Loss of appetite may occur.
- Weight loss may occur.
- Nausea or vomiting may occur.
- Ataxia (unsteady, uncoordinated movement) may occur.
- Low muscle tone (hypotonia) may occur.
- Tremor may occur.
- Increased saliva production may occur.
- Agitation or irritability may occur.
- Trouble sleeping or nightmares may occur.
- Abdominal pain may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Neutropenia (a drop in infection-fighting white blood cells) can occur and requires blood count monitoring before starting treatment and every 6 months afterward.
- A significant drop in platelet count (thrombocytopenia) can occur, raising the risk of bruising or bleeding.
- Liver enzyme elevations and, rarely, more serious liver injury such as cytolytic hepatitis can occur.
- Delirium and hallucinations have been reported rarely in adults, particularly those with a prior history of psychotic episodes.
- Movement disorders, including dystonia, increased or abnormal involuntary movements, and difficulty with speech (dysarthria), may occur.
- Severe loss of appetite and weight loss can lead to growth problems in children, requiring monitoring of height and weight.
- Antiepileptic drugs as a class, including stiripentol, may increase the risk of suicidal thoughts or behaviour.
- Serious skin reactions, including Stevens-Johnson syndrome, have been reported.
- Pneumonia and aspiration pneumonia have been reported.
- Pancreatitis has been reported.
- Thyroid inflammation (thyroiditis) has been reported.
- Seek urgent medical attention for signs of severe allergic reaction (facial swelling, difficulty breathing), unusual bruising or bleeding, signs of infection with fever, or yellowing of the skin or eyes.
Use with caution
- Use with caution in patients with liver impairment, since stiripentol is metabolized mainly by the liver and has not been formally studied in this population.
- Use with caution in patients with kidney impairment, since stiripentol's metabolites are cleared mainly by the kidney.
- Use with caution in patients with a history of psychosis or delirium, given reports of these effects during treatment.
- Use caution regarding driving or operating machinery, until the individual's response to stiripentol is known, given the risk of drowsiness, dizziness, and difficulty concentrating.
- Use with caution in patients with phenylketonuria when using the powder for suspension, since it contains aspartame.
- Use with caution when planning surgery, since stiripentol's enzyme-inhibiting effects can affect drugs used during or after the procedure.
- Monitor blood counts and liver function before starting treatment and every 6 months, or more often if clinically indicated.
- Monitor growth (height and weight) in children, given the frequency of appetite loss and weight loss with stiripentol combined with valproate and clobazam.
Contraindications
- Contraindicated in patients with known hypersensitivity to stiripentol or to any ingredient in the formulation or container.
Drug interactions
- Carbamazepine, phenytoin, and phenobarbital should not be used together with stiripentol in Dravet syndrome, since stiripentol raises their blood levels and increases the risk of toxicity.
- Stiripentol markedly raises clobazam levels (roughly two- to three-fold) and norclobazam levels (roughly five-fold), usually requiring a reduction in clobazam dose.
- Stiripentol has a modest interaction with valproate; no routine valproate dose change is needed, though the dose may need reducing if gastrointestinal side effects occur.
- Stiripentol inhibits CYP1A2, CYP2C8, CYP2C19, CYP2D6, and CYP3A4, and can markedly raise blood levels of drugs metabolized by these enzymes.
- Co-administration with CYP3A4 substrates that have a narrow safety margin, such as ergot alkaloids, cyclosporine, sirolimus, tacrolimus, quinidine, and fentanyl, should be avoided or approached with caution due to the risk of serious toxicity.
- Combining stiripentol with cisapride, halofantrine, pimozide, quinidine, or bepridil can raise the risk of dangerous heart rhythm disturbances.
- Combining stiripentol with statins such as atorvastatin or simvastatin can raise the risk of muscle toxicity (rhabdomyolysis).
- Combining stiripentol with benzodiazepines such as midazolam, triazolam, or alprazolam can cause excessive sedation.
- Combining stiripentol with theophylline or caffeine can raise blood levels of these substances and lead to toxicity; this combination should be avoided.
- Stiripentol can raise blood levels of other antiepileptic drugs metabolized by CYP2C19 or CYP3A4, including primidone, diazepam, ethosuximide, and tiagabine, requiring monitoring and possible dose adjustment.
- Combining stiripentol with drugs metabolized by CYP2D6, such as certain beta-blockers, antidepressants, antipsychotics, and opioid analgesics (codeine, tramadol, dextromethorphan), may require dose adjustment.
- Alcohol can add to the sedating effects of stiripentol and should be avoided.
- Chlorpromazine's central depressant effect may be enhanced by stiripentol.
Food interactions
- DIACOMIT must always be taken with food, since stiripentol degrades quickly in the acidic environment of an empty stomach.
- DIACOMIT should not be taken with milk or dairy products, carbonated drinks, fruit juice, or foods and drinks containing caffeine or theophylline, since these can affect its absorption or interact with its metabolism.
Time of administration
- Capsules should be swallowed whole with a glass of water during a meal, and should not be broken, opened, or chewed.
- Powder for suspension should be mixed in a glass of water and taken immediately after mixing, during a meal.
- DIACOMIT should be taken at consistent times each day.
Storage
- Store DIACOMIT in its original package to protect it from light, at room temperature (15°C to 30°C), in a dry place, out of the reach and sight of children.
Patient take-away
- DIACOMIT is an add-on antiepileptic used with clobazam and valproate specifically for Dravet syndrome and must always be taken with food.
- Regular blood tests are needed to monitor for neutropenia and liver problems.
- Never stop DIACOMIT abruptly; discontinuation must be gradual and supervised by a doctor.
- Report any signs of severe allergic reaction, unusual bruising or bleeding, mood or behaviour changes, or worsening seizures to a healthcare professional promptly.